The Patient View
The following discussion paper lays out a vision for a pharmaceutical strategy for Canada that focuses on catastrophic drug coverage and improved access to medications to improve outcomes. This paper also discusses health outcomes and recognizes that managing chronic diseases and their risk factors must be an essential feature of an effective pharmaceutical strategy. It also examines issues related to patient centered health care such as engaging patients in the management of their own health. The purpose of the discussion paper is to serve as a foundation for discussion and debate and as a tool for developing consensus.
By: Linda Wilhelm
Three months after completion, the National Pharmaceutical Taskforce released its progress report to Canadians. We are still impatiently waiting for the implementation of a National Pharmaceutical Strategy that will ensure that no Canadian suffers hardship in accessing needed medications.
The theme of this paper, from the perspective of the Health Charities Coalition of
Canada (HCCC), is that health-care consumers — patients, people with chronic and
progressive illnesses, and their immediate families — are under-represented throughout
Canada’s pharmaceutical regulatory system.